Athersys, Inc. Stock price

Equities

ATHXQ

US04744L2051

Biotechnology & Medical Research

Market Closed - OTC Markets 03:36:30 2024-03-27 pm EDT 5-day change 1st Jan Change
0.006 USD +7.14% Intraday chart for Athersys, Inc. +11.11% -70.00%
Sales 2021 5.51M Sales 2022 5.32M Capitalization 14.16M
Net income 2021 -87M Net income 2022 -72M EV / Sales 2021 33.5 x
Net cash position 2021 27.64M Net cash position 2022 353K EV / Sales 2022 2.59 x
P/E ratio 2021
-2.31 x
P/E ratio 2022
-0.14 x
Employees 24
Yield 2021 *
-
Yield 2022
-
Free-Float 99.23%
More Fundamentals * Assessed data
Dynamic Chart

Latest transcript on Athersys, Inc.

1 day+7.14%
1 week+11.11%
Current month-50.82%
1 month-44.95%
3 months-74.79%
6 months-98.17%
Current year-70.00%
More quotes
1 week
0.01
Extreme 0.0054
0.01
1 month
0.01
Extreme 0.005
0.02
Current year
0.00
Extreme 0.0045
0.04
1 year
0.00
Extreme 0.0045
1.31
3 years
0.00
Extreme 0.0045
49.50
5 years
0.00
Extreme 0.0045
109.50
10 years
0.00
Extreme 0.0045
109.50
More quotes
Managers TitleAgeSince
Director of Finance/CFO 50 22-07-31
Chief Tech/Sci/R&D Officer - 96-12-31
Investor Relations Contact - 23-01-31
Members of the board TitleAgeSince
Director/Board Member 68 10-05-31
Chairman 67 20-11-11
Director/Board Member 61 23-01-03
More insiders
Date Price Change Volume
24-03-27 0.006 +7.14% 56,465
24-03-26 0.0056 -13.85% 18,706
24-03-25 0.0065 0.00% 193,668
24-03-22 0.0065 +11.30% 99,677
24-03-21 0.00584 +8.15% 106,587

Delayed Quote OTC Markets, March 27, 2024 at 03:36 pm EDT

More quotes
Athersys, Inc. is a biotechnology company focused primarily on the field of regenerative medicine. The Company is engaged in the discovery and development of therapeutic product candidates to address unmet medical needs in multiple disease areas. Its MultiStem (invimestrocel) cell therapy, which is an allogeneic stem cell product candidate, is its lead platform product and is in late-stage clinical development. MultiStem cell therapy includes treatment of critical care indications, neurological conditions, inflammatory and immune disorders, certain pulmonary conditions, cardiovascular disease, and other conditions. MultiStem cell therapy is manufactured from human stem cells obtained from adult bone marrow and these cells are alternatively obtained from other tissue sources. It is conducting a Phase III clinical trial of MultiStem cell therapy for the treatment of ischemic stroke, referred to as MultiStem Administration for Stroke Treatment and Enhanced Recovery Study-2 (MASTERS-2).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
  1. Stock
  2. Equities
  3. Stock Athersys, Inc. - OTC Markets